ReviewTherapeutic advances in medical oncology2019
Current status of hepatocellular carcinoma detection: screening strategies and novel biomarkers.
Review in Therapeutic advances in medical oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed.
- Large-scale serum N-glycomics tracks N-glycosylation dynamics in hepatocellular carcinoma progression and enables early diagnosis.Nature communications · 2026Article
- Article
- Atezolizumab Plus Bevacizumab Combination Therapy in Unresectable Hepatocellular Carcinoma: An Institutional Experience.Biomedicines · 2025Article
- Preoperative ternary classification using DCE-MRI radiomics and machine learning for HCC, ICC, and HIPT.Insights into imaging · 2025Article
- Discovery and validation of a novel dual-target blood test for the detection of hepatocellular carcinoma across stages from cirrhosis.BMC medicine · 2025Article
- Development of a Novel four-gene Model for Monitoring the Progression from Metabolic Dysfunction-associated Steatotic Liver Disease to Hepatocellular Carcinoma in Males.Journal of Cancer · 2025Article
- Latest insights into the epidemiology, characteristics, and therapeutic strategies of chronic hepatitis B patients in indeterminate phase.European journal of medical research · 2024Review
- Tumor biomarkers for diagnosis, prognosis and targeted therapy.Signal transduction and targeted therapy · 2024Review
- Prevention in Hepatology.Journal of personalized medicine · 2024Review
- Development and clinical validation of a novel algorithmic score (GAAD) for detecting HCC in prospective cohort studies.Hepatology communications · 2023Article
- Integrated analysis of intratumoral biomarker and tumor-associated macrophage to improve the prognosis prediction in cancer patients.BMC cancer · 2023Article
- Construction and validation of a prognostic model based on autophagy-related genes for hepatocellular carcinoma in the Asian population.BMC genomics · 2023Article
- CRISPR activation screening in a mouse model for drivers of hepatocellular carcinoma growth and metastasis.iScience · 2023Article
- Clinicopathological and prognostic value of long non-coding RNA CCAT1 expression in patients with digestive system cancer.Oncology letters · 2023Article
- Advancements in Oncoproteomics Technologies: Treading toward Translation into Clinical Practice.Proteomes · 2023Review
- Immunotherapy, targeted therapy, and their cross talks in hepatocellular carcinoma.Frontiers in immunology · 2023Review
- Establishment and validation of a ferroptosis-related prognostic signature for hepatocellular carcinoma.Frontiers in oncology · 2023Article
- Hydroxymethylation and Epigenetic Drugs: New Insights into the Diagnosis and Treatment in Epigenetics of Hepatocellular Carcinoma.Journal of oncology · 2023Review
- Expert consensus on the role of hematological markers in the early clinical screening of hepatocellular carcinoma.Liver research (Beijing, China) · 2022Article
- Exosomal microRNA panel as a diagnostic biomarker in patients with hepatocellular carcinoma.Frontiers in cell and developmental biology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) remains a major cause of cancer-related mortality worldwide. Delayed diagnosis is a major factor responsible for the poor prognosis of HCC. Several advances have been made in the field of liver imaging with the use of novel imaging contrasts, improving current imaging techniques with contrast-enhanced computed tomography (CT) and magnetic resonance imaging (MRI), introduction of new technologies such as contrast liver ultrasound, and development of novel biomarkers with the goal of early detection of HCC and improving outcomes of patients with HCC. This review focuses on current surveillance strategies and development of biomarkers with the goal of early detection of HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.